<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655834</url>
  </required_header>
  <id_info>
    <org_study_id>IMPROVE-III</org_study_id>
    <nct_id>NCT03655834</nct_id>
  </id_info>
  <brief_title>Dose Individualization of Pemetrexed - IMPROVE-III</brief_title>
  <acronym>IMPROVE-III</acronym>
  <official_title>Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:&#xD;
&#xD;
      Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the&#xD;
      treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma. Dosing of&#xD;
      cytotoxic agents like pemetrexed requires balancing the dual risk of sub-therapy and&#xD;
      toxicity. Administration of pemetrexed to patients with a creatinine clearance &lt;45 ml/min is&#xD;
      currently not advised. Pemetrexed is dosed based on body surface area (BSA), while renal&#xD;
      function and dose are the sole determinants for systemic exposure. This causes 3 major&#xD;
      issues:&#xD;
&#xD;
        1. In patients with renal dysfunction, BSA-based dosing may lead to haematological toxicity&#xD;
&#xD;
        2. Patients have to discontinue treatment due to declining renal function, and are withheld&#xD;
           effective treatment&#xD;
&#xD;
        3. Even in patients with adequate renal function (GFR &gt;45 ml/min) treatment may be improved&#xD;
           by individualized dosing based on renal function, resulting in less toxicity. Also,&#xD;
           BSA-based dosing may lead to ineffective therapy in patients with above average renal&#xD;
           function.&#xD;
&#xD;
      The investigators aim to address these problems.&#xD;
&#xD;
      Objective: The overall main objective is to develop a safe and effective individualized&#xD;
      dosing regimen for pemetrexed.&#xD;
&#xD;
      Study design: IMPROVE-III is an explorative microdosing study to assess the extrapolability&#xD;
      of microdose-pharmacokinetics to the pharmacokinetics of a therapeutic dose.&#xD;
&#xD;
      Study population: IMPROVE-III includes 10 patients of IMPROVE-I and/or IMPROVE-II.&#xD;
&#xD;
      Intervention: patients will be administered a microdose with subsequent pharmacokinetic&#xD;
      assessment.&#xD;
&#xD;
      Main study endpoints: The predictive performance of microdosing to predict full dose&#xD;
      pharmacokinetics&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The predictive performance of microdosing to predict full dose pharmacokinetics</measure>
    <time_frame>3 months</time_frame>
    <description>Mean relative prediction error (MPE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The predictive performance of microdosing to predict full dose pharmacokinetics</measure>
    <time_frame>3 months</time_frame>
    <description>Root mean squared relative prediction error (RMSE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exposure (AUC) after microdose</measure>
    <time_frame>1 day</time_frame>
    <description>mg*h/l</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Microdosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered a microdose of pemetrexed with subsequent pharmacokinetic assessment. Afterwards the patients will continue in either IMPROVE-I or -II for second pharmacokinetic assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>patients will be administered a microdose with subsequent pharmacokinetic assessment.</description>
    <arm_group_label>Microdosing</arm_group_label>
    <other_name>Microdosing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. â‰¥18 years old&#xD;
&#xD;
          2. Planned for treatment with pemetrexed-based chemotherapy in IMPROVE-I or -II.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2&#xD;
&#xD;
          4. Subject is able and willing to sign the Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Conditions that affect haemostasis in a way that blood drawing is complicated (to be&#xD;
             assessed by physician)&#xD;
&#xD;
          2. Contraindications for treatment with pemetrexed in line with the summary of product&#xD;
             characteristics (SmPC) (except for creatinine clearance &lt;45 ml/min in IMPROVE-I)&#xD;
&#xD;
               1. Hypersensitivity to the active substance or to any of the excipients&#xD;
&#xD;
               2. Pregnancy or lactation&#xD;
&#xD;
               3. Concomitant yellow fever vaccine&#xD;
&#xD;
          3. The presence of clinically relevant pharmacokinetic interactions, according to the&#xD;
             current SmPC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob ter Heine, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rob ter Heine, PhD</last_name>
    <phone>+31 (0)24 361 7744</phone>
    <email>R.terHeine@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikki de Rouw, MSc</last_name>
    <phone>+31 (0)24 361 7744</phone>
    <email>R.terHeine@radboudmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bonne Biesma</last_name>
      <email>b.biesma@jbz.nl</email>
    </contact>
    <investigator>
      <last_name>Bonne Biesma</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeroen Derijks</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sjaak Burgers</last_name>
      <email>s.burgers@nki.nl</email>
    </contact>
    <investigator>
      <last_name>Sjaak Burgers</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alwin Huitema</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Marie Dingemans</last_name>
      <email>a.dingemans@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie Dingemans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud university medical centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rob ter Heine</last_name>
      <email>R.terHeine@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Rob ter Heine</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikki de Rouw</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel van den Heuvel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joachim Aerts</last_name>
      <email>j.aerts@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Joachim Aerts</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Mathijsen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

